Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET
Company Participants
Meredith Kaya - SVP, IR & Strategic Finance
Adam Townsend - Chief Commercial Officer
Cedric Francois - Co-Founder, President, CEO & Director
Timothy Sullivan - CFO & Treasurer
Federico Grossi - Chief Medical Officer
Conference Call Participants
Madhu Kumar - Goldman Sachs Group
Jonathan Miller - Evercore ISI
Joseph Stringer - Needham & Company
Philip Nadeau - Cowen and Company
Eliana Merle - UBS
Timur Ivannikov - Raymond James & Associates
Derek Archila - Wells Fargo Securities
Yigal Nochomovitz - Citigroup
Laura Chico - Wedbush Securities
Colleen Kusy - Robert W. Baird & Co.
Operator
Hello, and welcome to Apellis Pharmaceuticals First Quarter 2022 Earnings Conference Call. [Operator Instructions].
It is now my pleasure to introduce Senior Vice President of Investor Relations and Strategic Finance, Meredith Kaya.
Meredith Kaya
Good afternoon, and thank you for joining us to discuss Apellis's first quarter 2022 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Commercial Officer, Adam Townsend; Chief Medical Officer, Dr. Federico Grossi; and Chief Financial Officer, Tim Sullivan.
Before we begin, I would like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
Now, I'll turn the call over to Cedric.
Cedric Francois
Thank you all for joining us today. 2022 is off to an extraordinary start at Apellis as we continue to execute across each of our key priorities. Starting with intravitreal pegcetacoplan for geographic atrophy, or GA, we've made important progress as we prepare for the NDA submission later this quarter. We completed the pre-NDA meeting in January, and then in March, we shared 18-month data from our Phase III DERBY and OAKS studies determining that longer-term treatment with pegcetacoplan resulted in an increasing benefit to patients with greater amounts of retinal tissue saved over time and a favorable safety profile.
Additionally, these data showed improving effects in DERBY that were comparable with OAKS starting at month 6. Just this week at ARVO, we shared additional 18-month data analyses that showed that pegcetacoplan reduced lesion growth in patients with extrafoveal lesions and in patients with foveal lesions, further supporting pegcetacoplan's benefits for a diverse population of patients across the GA disease spectrum.